Intravitreal injection of conbercept
Eye Care
≈ ¥4800-6500
(≈ $670-910)
20 min
Disclaimer: This site is a medical service platform; some page content is AI-assisted. Health-related information does not constitute medical advice. If you have any questions, please consult a healthcare professional. See full disclaimer
Description
Estimated cost for Intravitreal injection of conbercept at general public hospitals in China is about ¥3360-5200, and at Grade 3A hospitals about ¥4800-6500, varying by hospital tier and region.
Main Uses
Primary clinical use is intravitreal treatment of neovascular (wet) age-related macular degeneration (nAMD), myopic choroidal neovascularization (mCNV), and diabetic macular edema (DME). It inhibits vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF), thereby reducing abnormal blood vessel growth, vascular leakage, and retinal edema. Administered as an off-label or approved (in China) therapy based on disease activity, anatomical response (OCT), and functional outcomes (visual acuity).
Normal Range
Not applicable — anti-VEGF intravitreal injection (Conbercept) is a therapeutic procedure, not a diagnostic laboratory test with quantitative biomarker values. There is no 'normal range' for the injection itself; efficacy and safety are assessed clinically via OCT, visual acuity, fundus imaging, and intraocular pressure monitoring.
Low Values - Possible Causes
N/A — 'Low value' is not meaningful for this intervention, as Conbercept is not a measurable circulating biomarker. However, suboptimal clinical response (e.g., persistent fluid or vision loss) may result from inadequate dosing frequency, poor drug penetration, tachyphylaxis, non-VEGF-driven pathology (e.g., inflammatory or fibrotic components), or patient-specific pharmacokinetic variability.
High Values - Possible Causes
N/A — 'High value' does not apply, as Conbercept administration is not quantified in systemic or ocular fluid concentrations post-injection for routine clinical decision-making. Excessive dosing may increase risks (e.g., intraocular inflammation, RPE atrophy, geographic atrophy, or sustained IOP elevation), but these are adverse events—not 'high values' of a test.
Related Items
Dry Eye Syndrome Treatment
≈ ¥20-50
Phacoemulsification with intraocular lens implantation
≈ ¥8000-25000
Femtosecond laser-assisted cataract surgery (FLACS)
≈ ¥18000-35000
YAG laser capsulotomy
≈ ¥300-800
Intravitreal injection of ranibizumab
≈ ¥4500-6500
Intravitreal aflibercept injection
≈ ¥4800-6500